NCT05628571

Brief Summary

The aim of this study is to evaluate the antibacterial effect 12 hours after 4-week use of a toothpaste containing amine base, zinc lactate, and fluoride. For this, healthy people will be invited to use two different toothpaste: control - containing only fluoride; test - containing fluoride plus a combination with zinc. The primary outcome is the efficacy of the test toothpaste in the oral bacterial load reduction in samples of saliva and oral mucosa (obtained through scraping); the second outcome is effect of the test toothpaste in the expression of mucin in the oral mucosa.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
130

participants targeted

Target at P25-P50 for phase_3

Timeline
Completed

Started Feb 2023

Shorter than P25 for phase_3

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 7, 2022

Completed
21 days until next milestone

First Posted

Study publicly available on registry

November 28, 2022

Completed
2 months until next milestone

Study Start

First participant enrolled

February 1, 2023

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 30, 2023

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2023

Completed
Last Updated

January 12, 2023

Status Verified

November 1, 2022

Enrollment Period

3 months

First QC Date

November 7, 2022

Last Update Submit

January 11, 2023

Conditions

Keywords

toothpastesfluorideantimicrobial effectoral bacteriamucinzinc

Outcome Measures

Primary Outcomes (1)

  • Change of oral bacteria load

    analysis of oral bacterial load (log10 colony-forming unit/mL) in saliva and oral mucosa biofilm samples, performed by microbial culture

    Baseline (previously of the interventions) and after 4 weeks of the interventions

Secondary Outcomes (1)

  • Change of mucin expression in oral mucosa samples

    Baseline (previously of the interventions) and after 1, 2, 3 and 4 weeks of the interventions

Study Arms (2)

Fluoride toothpaste

PLACEBO COMPARATOR

Participants will brush their teeth with a commercially available Fluoride toothpaste (1450 ppm F) and a commercially available adult soft bristle toothbrush

Combination Product: Fluoride Toothpaste

Zinc toothpaste

EXPERIMENTAL

Participants will brush their teeth with a toothpaste containing amine base, zinc lactate and fluoride (1400 ppm F) and a commercially available adult soft bristle toothbrush

Combination Product: Zinc toothpaste

Interventions

Zinc toothpasteCOMBINATION_PRODUCT

Participants will brush their teeth with a commercially available, soft-bristle adult toothbrush and toothpaste containing amine-based zinc lactate (0.1%) and fluoride (1400 ppm F).

Zinc toothpaste
Fluoride ToothpasteCOMBINATION_PRODUCT

Participants will brush their teeth with a commercially available, soft-bristle adult toothbrush and toothpaste containing fluoride (1450 ppm F).

Fluoride toothpaste

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male and female subjects, ages 18-70, inclusive;
  • Subjects are available during study duration;
  • Subject is in good general health;
  • A minimum of 15 natural teeth with facial and lingual scorable surfaces, excluding third molars.
  • A willingness to read, understand, and sign the Informed Consent Form after the nature of the study has been fully explained to them.
  • Subjects with baseline whole mouth scores of dental plaque of 1.5 or more and gingivitis index of 1.0 or more.

You may not qualify if:

  • Participation in any other clinical study or test panel including clinical studies with oral hygiene formulations within the one month prior to entry into the study.
  • History of dental prophylaxis or treatments in the past month or during study duration.
  • History of medical treatments (e.g: antibiotic, anti-inflammatory, anticoagulant, etc.) during the month preceding study enrollment.
  • Subjects scheduled for any medical procedure during the course of the study.
  • Difficulty complying with study procedures and examinations such as excessive gagging during oral assessment etc.
  • History of significant adverse effects following use of oral hygiene products such as toothpastes and mouthrinses. Allergies to personal care/consumer products or their ingredients.
  • History of diabetes, hepatic, renal disease, inflammatory conditions or transmittable diseases, e.g. heart disease or AIDS.
  • History of rheumatic fever or medical conditions that require prophylactic antibiotics coverage prior to dental procedures.
  • Presence of oral lesions.
  • History of active or severe periodontal disease (PD \> 4) and loose teeth.
  • Gross dental caries, severe generalized cervical abrasion and/or enamel abrasion, large fractured or temporary restorations (based on visual examinations).
  • Fixed or removable orthodontic appliances or removable partial dentures.
  • Current smokers and subjects with a history of alcohol or drug abuse.
  • Use of phenolic flavored products, such as mint flavored candies and chewing gum, during the study period.
  • Unable to refrain from oral hygiene for twelve (12) hours prior to scheduled visits.
  • +1 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (7)

  • Aguirre A, Mendoza B, Levine MJ, Hatton MN, Douglas WH. In vitro characterization of human salivary lubrication. Arch Oral Biol. 1989;34(8):675-7. doi: 10.1016/0003-9969(89)90024-1.

    PMID: 2597059BACKGROUND
  • Ben Lagha A, Yang Y, Trivedi HM, Masters JG, Grenier D. A Dual Zinc plus Arginine formulation attenuates the pathogenic properties of Porphyromonas gingivalis and protects gingival keratinocyte barrier function in an in vitro model. J Oral Microbiol. 2020 Aug 4;12(1):1798044. doi: 10.1080/20002297.2020.1798044.

    PMID: 32944154BACKGROUND
  • Carda-Dieguez M, Moazzez R, Mira A. Functional changes in the oral microbiome after use of fluoride and arginine containing dentifrices: a metagenomic and metatranscriptomic study. Microbiome. 2022 Sep 28;10(1):159. doi: 10.1186/s40168-022-01338-4.

    PMID: 36171634BACKGROUND
  • Creeth JE, Karwal R, Hara AT, Zero DT. A Randomized in situ Clinical Study of Fluoride Dentifrices on Enamel Remineralization and Resistance to Demineralization: Effects of Zinc. Caries Res. 2018;52(1-2):129-138. doi: 10.1159/000479823. Epub 2018 Jan 5.

    PMID: 29301123BACKGROUND
  • Delgado E, Garcia-Godoy F, Montero-Aguilar M, Mateo LR, Ryan M. A Clinical Investigation of a Dual Zinc plus Arginine Dentifrice in Reducing Established Dental Plaque and Gingivitis Over a Six-Month Period of Product Use. J Clin Dent. 2018 Sep;29(Spec No A):A33-40.

    PMID: 30620869BACKGROUND
  • Kindblom C, Davies JR, Herzberg MC, Svensater G, Wickstrom C. Salivary proteins promote proteolytic activity in Streptococcus mitis biovar 2 and Streptococcus mutans. Mol Oral Microbiol. 2012 Oct;27(5):362-72. doi: 10.1111/j.2041-1014.2012.00650.x. Epub 2012 May 25.

    PMID: 22958385BACKGROUND
  • Manus LM, Daep CA, Begum-Gafur R, Makwana E, Won B, Yang Y, Huang XY, Maloney V, Trivedi HM, Wu D, Masters JG. Enhanced In Vitro Zinc Bioavailability through Rational Design of a Dual Zinc plus Arginine Dentifrice. J Clin Dent. 2018 Sep;29(Spec No A):A10-19.

    PMID: 30620866BACKGROUND

MeSH Terms

Conditions

Medullary cystic kidney disease 1

Interventions

green tea bioflavonoid, zinc ascorbate-containing toothpaste

Central Study Contacts

Leticia M Bezinelli, PhD

CONTACT

Fernanda de P Eduardo, PhD

CONTACT

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Masking Details
Randomization lists will be kept confidential by the Investigator, inside a locked cabinet. As patients are included by the Examiner at the first visit (T0), the Investigator will make the allocation. The Examiner and other team members, including the Laboratory Technician, will not know the group to which the patient belongs. Toothpastes will be covered with white paper to disguise the identity of the product. Participants will also not know which group they belong to and which investigational product they are using. To this end, the products will be distributed in a separate area of the exam room by the Assistant, without the other participants being present. The samples will also be labeled with the information of the participant's first and last name initials, the randomization code and the sample collection data (type, intraoral location and collection date). The Laboratory Technician will not know which group the sample belongs to.
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 7, 2022

First Posted

November 28, 2022

Study Start

February 1, 2023

Primary Completion

April 30, 2023

Study Completion

June 30, 2023

Last Updated

January 12, 2023

Record last verified: 2022-11

Data Sharing

IPD Sharing
Will not share

All study data will be recorded on forms provided by the sponsor. Only the Investigator, Examiner and Assistant may make entries on the forms. Source data will be retained by the study site. Record security will include keeping written forms in locked and/or sealed file cabinets and/or labeled storage boxes located in a locked room. Access will be denied to all persons except the Principal Investigator and his designees.